LACTB and tuberculosis: The development of the potent subclass of carbapenems and the addition of clavulanate or other protective beta-lactamase inhibitors (Hugonnet and Blanchard, 2007), have led to the revaluation of the role of the beta-lactams within TB regimens (Story-Roller and Lamichhane, 2018; Catalão et al., 2019).